Hemodialysis does not affect everolimus pharmacokinetics: two cases of patients with metastatic renal cell cancer
A Thiery-Vuillemin, E Curtit, T Maurina… - Annals of …, 2012 - annalsofoncology.org
Everolimus was shown to increase the progression-free survival of patients with advanced
renal cell carcinoma (RCC) after failure of tyrosine kinase inhibitors targeting angiogenesis
[1]. However, in clinical practice, physicians are confronted with the question of whether
patients with metastatic RCC (mRCC) and terminal renal failure who require hemodialysis
(HD) can be safely treated with everolimus. Clinical trials leading to the approval have
excluded these patients. When everolimus is used as an immunomodulatory agent to …
renal cell carcinoma (RCC) after failure of tyrosine kinase inhibitors targeting angiogenesis
[1]. However, in clinical practice, physicians are confronted with the question of whether
patients with metastatic RCC (mRCC) and terminal renal failure who require hemodialysis
(HD) can be safely treated with everolimus. Clinical trials leading to the approval have
excluded these patients. When everolimus is used as an immunomodulatory agent to …
以上显示的是最相近的搜索结果。 查看全部搜索结果